ArticleIndian journal of endocrinology and metabolism
Obese and Non-obese Polycystic Ovarian Syndrome: Comparison of Clinical, Metabolic, Hormonal Parameters, and their Differential Response to Clomiphene.
Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06551285 (Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Comparison of Clinical, Metabolic, and Hormonal Profiles in Obese Versus Lean Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2026Pooled it
- Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.The Cochrane database of systematic reviews · 2019 · on this mapPooled it
- BMI-stratified phenotypes of polycystic ovary syndrome: advances in gut microbiota research and personalized management strategies.Frontiers in endocrinology · 2026Review
- Evaluation of serum calprotectin levels in patients with polycystic ovary syndrome.Scientific reports · 2025Article
- CAPN2 correlates with insulin resistance states in PCOS as evidenced by multi-dataset analysis.Journal of ovarian research · 2024Article
- Article
- Exploratory factor and confirmatory analyses of the polycystic ovary syndrome health-related quality of life questionnaire (PCOSQ-50).Health and quality of life outcomes · 2024Article
- Mitochondrial DNA oxidation and content in different metabolic phenotypes of women with polycystic ovary syndrome.Frontiers in endocrinology · 2024Article
- Dual-energy X-ray absorptiometry and adiposity index are sensitive methods to evaluate central fat accumulation in women with polycystic ovary syndrome and normal body mass index.Archives of endocrinology and metabolism · 2023Article
- Predictors of response to ovulation induction using letrozole in women with polycystic ovary syndrome.BMC endocrine disorders · 2023Article
- Levels of Trace Elements in Erythrocytes as Endocrine Disruptors in Obese and Nonobese Women with Polycystic Ovary Syndrome.International journal of environmental research and public health · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the clinical, metabolic, hormonal parameters, and differential response to clomiphene among the obese and non-obese PCOS (polycystic ovarian syndrome).
designProspective observational study.
settingInfertility OPD, a government hospital. SAMPLE SIZE: About 164 women with PCOS-related infertility. STUDY GROUPS: Obese PCOS group [body mass index (BMI) ≥23 kg/m
resultsOf the total 164 PCOS women, 124 (75.61%) were in the obese group with BMI ≥23 kg/m
conclusionObese PCOS have a higher risk of adverse outcomes like hypertension, IR, metabolic syndrome, and endometrial hyperplasia. So, targeting obesity in PCOS women will not only help to prevent adverse outcomes but also improve responsiveness to clomiphene citrate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.